IL164812A0 - Packaged virus-like particles for use as adjuvants: method of preparation and use - Google Patents

Packaged virus-like particles for use as adjuvants: method of preparation and use

Info

Publication number
IL164812A0
IL164812A0 IL16481204A IL16481204A IL164812A0 IL 164812 A0 IL164812 A0 IL 164812A0 IL 16481204 A IL16481204 A IL 16481204A IL 16481204 A IL16481204 A IL 16481204A IL 164812 A0 IL164812 A0 IL 164812A0
Authority
IL
Israel
Prior art keywords
vlps
antigens
packaged
adjuvants
particles
Prior art date
Application number
IL16481204A
Other languages
English (en)
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of IL164812A0 publication Critical patent/IL164812A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001104Epidermal growth factor receptors [EGFR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001106Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129Molecules with a "CD" designation not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001148Regulators of development
    • A61K39/00115Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151Apoptosis related proteins, e.g. survivin or livin p53
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001156Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001169Tumor associated carbohydrates
    • A61K39/001171Gangliosides, e.g. GM2, GD2 or GD3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00118Cancer antigens from embryonic or fetal origin
    • A61K39/001182Carcinoembryonic antigen [CEA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00119Melanoma antigens
    • A61K39/001191Melan-A/MART
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00119Melanoma antigens
    • A61K39/001192Glycoprotein 100 [Gp100]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588Adjuvants of undefined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6075Viral proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123Virus like particles [VLP]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
IL16481204A 2002-06-20 2004-06-20 Packaged virus-like particles for use as adjuvants: method of preparation and use IL164812A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38989802P 2002-06-20 2002-06-20
PCT/EP2003/006541 WO2004000351A1 (en) 2002-06-20 2003-06-20 Packaged virus-like particles for use as adjuvants: method of preparation and use

Publications (1)

Publication Number Publication Date
IL164812A0 true IL164812A0 (en) 2005-12-18

Family

ID=30000481

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16481204A IL164812A0 (en) 2002-06-20 2004-06-20 Packaged virus-like particles for use as adjuvants: method of preparation and use

Country Status (17)

Country Link
US (2) US20040005338A1 (pl)
EP (1) EP1513552B1 (pl)
JP (1) JP4598519B2 (pl)
CN (1) CN1662253A (pl)
AT (1) ATE489969T1 (pl)
AU (1) AU2003242742B2 (pl)
BR (1) BR0311995A (pl)
CA (1) CA2488856A1 (pl)
DE (1) DE60335186D1 (pl)
HK (1) HK1074578A1 (pl)
IL (1) IL164812A0 (pl)
MX (1) MXPA04011210A (pl)
NZ (1) NZ537002A (pl)
PL (1) PL375306A1 (pl)
RU (1) RU2322257C2 (pl)
WO (1) WO2004000351A1 (pl)
ZA (1) ZA200408709B (pl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
WO2004078965A1 (ja) * 2003-03-05 2004-09-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 大腸菌における異種蛋白質の製造方法
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
ZA200507562B (en) * 2003-03-26 2006-11-29 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
EP1644034B1 (en) * 2003-07-10 2011-01-12 Cytos Biotechnology AG Composition for enhancing an immune response comprising packaged virus-like particles
EP1646427A1 (en) * 2003-07-22 2006-04-19 Cytos Biotechnology AG Cpg-packaged liposomes
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
JP3976742B2 (ja) 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
WO2006033679A2 (en) * 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
WO2006032674A1 (en) * 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide
EP1812051A2 (en) * 2004-10-05 2007-08-01 Cytos Biotechnology AG Vlp-antigen conjugates and their uses as vaccines
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
EP1973608A1 (en) * 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
CN100418583C (zh) * 2006-02-21 2008-09-17 朱鸿飞 预防和治疗乳腺炎的药物组合物
AU2007348315A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating B- cell malignancies
AU2013204383B2 (en) * 2006-06-12 2016-09-22 Kuros Us Llc Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
KR101552227B1 (ko) 2006-06-12 2015-09-10 사이토스 바이오테크놀로지 아게 올리고뉴클레오티드를 rna 박테리오파지의 바이러스-유사 입자로 패키징하는 방법
AU2007345768B2 (en) * 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
US20100047266A1 (en) * 2006-07-27 2010-02-25 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
US7955603B2 (en) 2006-09-29 2011-06-07 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
AU2007333147B2 (en) * 2006-12-12 2013-12-19 Kuros Us Llc Oligonucleotides containing high concentrations of guanine monomers
US20090226525A1 (en) * 2007-04-09 2009-09-10 Chimeros Inc. Self-assembling nanoparticle drug delivery system
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US8986597B2 (en) * 2007-10-31 2015-03-24 Corning Incorporated Low creep refractory ceramic and method of making
WO2009060440A1 (en) * 2007-11-05 2009-05-14 Mor Research Applications Ltd. Anti-measles cancer immunotherapy
NO339169B1 (no) * 2008-04-24 2016-11-14 Chemoforma Ltd Funksjonelt fiskefôr omfattende peptidoglykan og nukleotider
WO2010017542A1 (en) * 2008-08-08 2010-02-11 Ligocyte Pharmaceuticals, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
RU2015151857A (ru) 2008-12-02 2019-01-15 Уэйв Лайф Сайенсес Джапан, Инк. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
EP2419143B8 (en) * 2009-04-13 2018-06-27 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
WO2011005761A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc Novel nucleic acid prodrugs and methods use thereof
EP2496609A4 (en) 2009-11-03 2013-05-08 Ligocyte Pharmaceuticals Inc CHIMERIC RSV-F POLYPEPTIDE AND VLPS ON LENTIVIREN OR ALPHA RETROVIRUS GAG BASE
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
EA025417B1 (ru) * 2010-11-22 2016-12-30 Борис Славинович ФАРБЕР Вакцины с повышенной иммуногенностью и способы их получения
KR101376675B1 (ko) * 2011-04-19 2014-03-20 광주과학기술원 이미징 및 운반 이중기능 나노입자-기반 백신 전달체
TWI454478B (zh) * 2011-05-13 2014-10-01 Academia Sinica 類鐸受體-2 增效劑及其用於刺激免疫反應之用途
ES2656527T3 (es) 2011-07-11 2018-02-27 Takeda Vaccines, Inc. Formulaciones parenterales de vacunas de norovirus
MX347361B (es) 2011-07-19 2017-04-12 Wave Life Sciences Ltd Metodos para la sintesis de acidos nucleicos funcionalizados.
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
CN102512671A (zh) * 2011-12-16 2012-06-27 厦门大学 抗o型口蹄疫的类病毒颗粒疫苗及其制备方法
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
CN103421117B (zh) * 2012-05-16 2016-08-03 李岱宗 一种免疫增强型病毒样颗粒、其表达载体及其制备与应用
CA2879023C (en) 2012-07-13 2017-03-28 Wave Life Sciences Japan Asymmetric auxiliary group
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
WO2015024992A2 (en) * 2013-08-22 2015-02-26 Cytos Biotechnology Ag Treatment of asthma
ES2917573T3 (es) 2013-09-18 2022-07-08 Aura Biosciences Inc Método de producción de moléculas fotosensibles
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design
US20150355147A1 (en) * 2014-06-06 2015-12-10 Biogénesis Bagó Uruguay S.A. High throughput quantification and characterization of foot and mouth disease virus and products thereof
WO2016054421A1 (en) 2014-10-02 2016-04-07 Protiva Biotherapeutics, Inc Compositions and methods for silencing hepatitis b virus gene expression
US10251970B1 (en) 2014-12-30 2019-04-09 Zee Company Air sanitation apparatus for food processing tanks having air agitation piping and methods thereof
MX2018005468A (es) 2015-10-30 2018-11-09 The Us Secretary Department Of Health And Man Services Terapia dirigida contra el cáncer.
CN108779473A (zh) * 2016-03-16 2018-11-09 法国居里学院 用于制备具有环二核苷酸的病毒颗粒的方法和所述颗粒用于治疗癌症的用途
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens
TWI634899B (zh) * 2016-11-22 2018-09-11 國立臺灣大學 包含類b肝病毒顆粒作為佐劑的疫苗組成物
CN112236522A (zh) 2018-04-09 2021-01-15 查克美特制药公司 寡核苷酸包装到病毒样颗粒中
US20220111040A1 (en) * 2018-08-07 2022-04-14 Institute Of Biophyscis, Chinese Academy Of Sciences Method for activating cd4+t cell
CN110257922A (zh) * 2019-07-19 2019-09-20 苏州盛天力离心机制造有限公司 羽毛洗涤脱水一体机
CA3149390A1 (en) * 2019-07-30 2021-02-04 Verndari, Inc. Virus-like particle vaccines
JP7072604B2 (ja) * 2020-06-23 2022-05-20 アンスティテュ・クリー 環状ジヌクレオチドを含むウイルス粒子を調製する方法及びがんを治療するための前記粒子の使用
WO2022051401A1 (en) * 2020-09-02 2022-03-10 The Regents Of The University Of California Covid assay controls
CN114632148A (zh) * 2020-12-15 2022-06-17 榕森生物科技(北京)有限公司 病原样抗原疫苗及其制备方法
CN115927400A (zh) * 2022-08-11 2023-04-07 中国动物卫生与流行病学中心 一种含口蹄疫病毒rna片段的假病毒颗粒及其制备方法和应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
US4918166A (en) * 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
SG48759A1 (en) * 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5334394A (en) * 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
GB9114003D0 (en) * 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
US5928647A (en) * 1993-01-11 1999-07-27 Dana-Farber Cancer Institute Inducing cytotoxic T lymphocyte responses
AU6172194A (en) * 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0732936B1 (de) * 1993-12-09 2000-03-29 Heinrich Exner Adjuvans für antigene, verfahren zur herstellung und verwendung
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE328890T1 (de) * 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5770380A (en) * 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998050071A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
EP1003531B1 (en) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
CA2295321C (en) * 1997-06-23 2008-01-29 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to hla molecules, and the use thereof
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US6231864B1 (en) * 1998-02-12 2001-05-15 Immune Complex Corporation Strategically modified hepatitis B core proteins and their derivatives
NZ508650A (en) * 1998-05-14 2003-05-30 Coley Pharm Gmbh Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
DK1104306T3 (da) * 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
US5962636A (en) * 1998-08-12 1999-10-05 Amgen Canada Inc. Peptides capable of modulating inflammatory heart disease
EP1135162B1 (en) * 1998-11-30 2008-10-29 Cytos Biotechnology AG Ordered molecular presentation of allergens, method of preparation and use
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CA2388055A1 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
JP2003527352A (ja) * 2000-01-13 2003-09-16 アンティジェニクス インコーポレーテッド Cpgおよびサポニンの自然免疫刺激化合物、ならびにそれらの方法
EP1311288A1 (en) * 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
AU2001252458A1 (en) * 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
WO2002026209A2 (en) * 2000-09-28 2002-04-04 Chiron Corporation Microparticles for delivery of the heterologous nucleic acids
NZ525320A (en) * 2000-10-18 2004-10-29 Glaxosmithkline Biolog S Combinations of immunostimulatory oligonucleotides (CpG), saponin and optionally lipopolysaccharides as potent vaccine adjuvants
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
CA2492826C (en) * 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
WO2004007538A2 (en) * 2002-07-17 2004-01-22 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
KR101228376B1 (ko) * 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
US20040076645A1 (en) * 2002-07-19 2004-04-22 Bachmann Martin F. Ghrelin-carrier conjugates
ZA200507562B (en) * 2003-03-26 2006-11-29 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates

Also Published As

Publication number Publication date
MXPA04011210A (es) 2005-02-14
RU2005101206A (ru) 2005-06-27
JP4598519B2 (ja) 2010-12-15
CA2488856A1 (en) 2003-12-31
CN1662253A (zh) 2005-08-31
US20040005338A1 (en) 2004-01-08
HK1074578A1 (en) 2005-11-18
WO2004000351A1 (en) 2003-12-31
AU2003242742A1 (en) 2004-01-06
AU2003242742B2 (en) 2009-04-30
ATE489969T1 (de) 2010-12-15
US20110070267A1 (en) 2011-03-24
NZ537002A (en) 2006-06-30
EP1513552B1 (en) 2010-12-01
WO2004000351A8 (en) 2005-02-03
BR0311995A (pt) 2005-04-05
ZA200408709B (en) 2005-11-18
RU2322257C2 (ru) 2008-04-20
DE60335186D1 (de) 2011-01-13
EP1513552A1 (en) 2005-03-16
JP2006502979A (ja) 2006-01-26
PL375306A1 (pl) 2005-11-28

Similar Documents

Publication Publication Date Title
IL164812A0 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
HK1067058A1 (en) Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
WO2004084939A3 (en) Hiv-peptide-carrier-conjugates
Skrastina et al. Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
DE602004031017D1 (de) Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
Martínez-Donato et al. Protective T cell and antibody immune responses against hepatitis C virus achieved using a biopolyester-bead-based vaccine delivery system
WO2002034205A3 (en) Using heat shock proteins to increase immune response
WO2001082963A3 (en) Method of identifying and producing antigen peptides and use thereof as vaccines
NO20062674L (no) Optimalisert uttrykking av HPV58-L1 i gjaer
WO2004084936A8 (en) Modified free-living microbes, vaccine compositions and methods of use thereof
EP1246644A4 (en) INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN PAPILLOMA VIRUS USING PEPTIDES AND NUCLEIC ACID COMPOSITIONS
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
WO2005009463A3 (en) Antigen-presenting cell vaccines and methods of use thereof
WO2004058157A3 (en) Yeast-based vaccines as immunotherapy
Mohammed et al. Cancer vaccines: past, present, and future
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
JP2011519869A5 (pl)
WO2009080715A3 (en) Vaccines for malaria
WO2005007673A3 (en) Immunogenic peptides
Wang et al. Immune responses to varicella-zoster virus glycoprotein E formulated with poly (lactic-co-glycolic acid) nanoparticles and nucleic acid adjuvants in mice
WO2008082719A3 (en) Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
NZ516725A (en) Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
Guillen et al. Virus-like particles as nanovaccine candidates
WO2020051566A1 (en) Vaccines with enhanced immune response and methods for their preparation